Elanco Animal Health Stock Price, News & Analysis

Elanco Animal Health (NYSE: ELAN) announced significant changes to its Board of Directors, reducing the board size to 11 directors by the 2025 Annual Meeting. Three directors - JP Bilbrey, Kathy Turner, and Craig Wallace - will not seek re-election, while William F. Doyle has resigned immediately.

Paul Herendeen will succeed Bilbrey as Chair of the Board's Finance, Strategy and Oversight Committee. The company recently added Dr. Stacey Ma to refresh Board composition.

Additionally, Elanco signed a research agreement with WEDterinary , a newly formed research entity co-founded by Doyle. The partnership will focus on:

• Developing targeted gene therapy treatments for Chronic Kidney Disease (CKD) in cats
• Exploring innovative approaches to increase healthy lifespan in pets
• Utilizing new technologies like gene therapy and AI

The research agreement will be funded within Elanco's existing R&D operating expenses.

Elanco Animal Health (NYSE: ELAN) has entered an agreement with South Dakota-based Medgene to commercialize a highly pathogenic avian influenza (HPAI) vaccine for dairy cattle. Medgene reports the vaccine has met all USDA platform technology requirements and is in final stages of review for conditional license approval.

The current HPAI outbreak has entered its fourth year, with cross-species transmission affecting nearly 1,000 dairy herds across the U.S. since March 2024. The virus is predicted to persist, making a cattle vaccine critical to slow transmission between birds and cattle.

Jeff Simmons, President and CEO of Elanco, stated the partnership will provide options to fight this disease and believes the product will become part of routine vaccination protocols for U.S. dairy. Mark Luecke, CEO of Medgene, noted their company has existing vaccine manufacturing supply ready to deploy with capacity to support the U.S. dairy herd.

Elanco Animal Health (NYSE: ELAN) reported its Q4 and full year 2024 results, showing Q4 revenue of $1,020 million (down 1% reported, up 4% organic constant currency) and full year revenue of $4,439 million (flat reported, up 3% organic constant currency).

Q4 highlights include Pet Health revenue of $439 million (up 6%) and Farm Animal revenue of $570 million (down 7% reported, up 2% organic constant currency). The company reported a Q4 net loss of $8 million ($(0.02) per share) but Adjusted EBITDA of $177 million (17.4% of revenue).

For full year 2024, Elanco achieved Adjusted EBITDA of $910 million (20.5% of revenue), reported EPS of $0.68, and Adjusted EPS of $0.91. The company exceeded its innovation revenue target at $461 million and reduced its net leverage ratio to 4.3x.

For 2025, Elanco maintained its November outlook except for incorporating an estimated FX headwind of $110 million to revenue, $45 million to Adjusted EBITDA, and $0.07 to Adjusted EPS. The company raised its 2025 innovation revenue target to $640-$720 million and expects mid-single digit organic constant currency revenue growth.

Elanco Animal Health (NYSE: ELAN) has announced its participation in three upcoming investor conferences in February and March 2025. Todd Young, executive vice president and CFO, will participate in fireside chats at the Bank of America Animal Health Summit on February 27 at 12:30 p.m. ET and the Barclays Global Healthcare Conference on March 11 at 9:00 a.m. ET.

Jeff Simmons, president and CEO, will join a fireside chat at the TD Cowen Annual Health Care Conference on March 3 at 3:10 p.m. ET. All sessions will be available via live audio webcasts in the 'Events and Presentations' section of Elanco's investor website, with replays available for a time after each event.

Elanco Animal Health (NYSE: ELAN) has launched Pet Protect, a new line of veterinarian-formulated supplements for dogs and cats. The launch comes as the U.S. pet supplement market reached $2.7 billion in 2023, growing at a CAGR of 20% over the past five years.

The Pet Protect line includes products for joint health, multivitamins, digestive function, calming, and skin health. Notable products include the Synovi G3 formula for joint health, DVM Daily Soft Chews for overall wellness, Lactoquil for digestive health, and a fast-acting Tranquilify™ blend for situational stress that works within 30 minutes.

The product line leverages the reputation of the Advantage brand, which has been a trusted leader in pet health for 25 years. Pet Protect is distinguished by being veterinarian-formulated, science-backed, and has earned the NASC® quality seal.

Elanco Animal Health has received a warning letter from the FDA regarding promotional materials for Zenrelia™, their prescription medication for dogs. The letter addresses statements in promotional materials for the drug, which is used to control itching and inflammation associated with skin allergies in dogs over 12 months old.

The company states they are working to review and update the promotional materials as requested, while emphasizing that the warning is not related to the product's actual performance in the market. Elanco maintains its financial outlook, expecting mid-single digit organic constant currency revenue growth in 2025, and does not anticipate material impact on Zenrelia revenue.

Important safety information for Zenrelia includes warnings about vaccine-induced disease risks and the need to discontinue use 28 days to 3 months prior to vaccination. The medication carries risks of infections and neoplastic conditions, with common side effects including vomiting, diarrhea, and tiredness.

Elanco Animal Health (NYSE: ELAN) has scheduled its fourth quarter and full year 2024 financial results announcement for Tuesday, February 25, 2025. The company will host a conference call at 8:00 a.m. eastern time to discuss the results with investors, media, and the general public.

A live webcast of the conference call will be accessible through Elanco's investor relations website, with a replay available shortly after the call concludes.

Elanco Animal Health (NYSE: ELAN) introduces Zenrelia™, an FDA-approved once-daily oral JAK inhibitor for controlling itching associated with allergic dermatitis in dogs aged 12+ months. The treatment, launched in September 2024, addresses a significant market with approximately 17 million U.S. dogs suffering from allergic skin diseases.

A newly published study in Veterinary Dermatology compared Zenrelia to Apoquel® in over 300 allergic dogs. The medication includes a boxed warning regarding concurrent vaccine administration. Real-world cases demonstrate successful treatment outcomes, with several dogs showing significant improvement in their conditions, including reduced itching and fur regrowth.

According to a survey, 82% of pet owners with itchy dogs dream of returning to normal life with their pets. The company has launched a dedicated platform, ZenreliaForVets.com, for U.S. veterinarians to learn more and place orders.

Elanco Animal Health (NYSE: ELAN) has launched Credelio Quattro, a new monthly chewable tablet for dogs that provides six-in-one parasite protection. The product is the first of its kind to protect against tapeworms, roundworms, hookworms, heartworms, ticks, and fleas in a single tablet.

The launch marks a significant milestone as it completes Elanco's portfolio of six potential blockbuster products in the U.S. market. According to company research, 94% of dog owners prioritize proactive treatment for intestinal worms. Studies show Credelio Quattro is 100% efficacious against tapeworms and kills ticks twice as fast as competing products.

The product addresses a significant market gap, as only one-third of pet owners believe fleas and ticks are a year-round risk, and only half provide year-round heartworm protection.